Home >> HealthCenter >> ClinicalTrial

"The Evaluation of Stimulant Withdrawal" (MARC)

This study is currently recruiting participants.
Verified by National Institute on Drug Abuse (NIDA) March 2007

Sponsored by:

National Institute on Drug Abuse (NIDA)

Information provided by:

National Institute on Drug Abuse (NIDA)

ClinicalTrials.gov Identifier:

NCT00442923

 

Purpose

The purpose of this research study is to determine whether Carvedilol, an FDA approved beta blocker, when administered for an 8-week period to veterans currently undergoing treatment for methamphetamine dependence (1) improves their ability to stay in treatment longer, (2)eases the aversive symptoms that accompany stimulant withdrawal, and (3) increases the time they remain abstinent from methamphetamine.

Condition

Intervention

Phase

Anxiety
Relapse
Substance Addiction

 Drug: Coreg

Phase II

MedlinePlus related topics:  Drug Abuse

Study Type: Interventional
Study Design: Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study

Official Title: Scientific Component IV: Pharmacotherapy to Prevent Methamphetamine Relapse

 

1234
Next

Home   |   About Us   |   Contact Us   |   Privacy   |   Terms Of Use   |   Advertise With Us   |   Sitemap
Copyright © 2022 Responsive Health
This site is intended to provide you with health information from publicly available sources, supporting vendors and partnered sources. While We make every effort to ensure that the information on this site is accurate, We make absolutely no assumption, inference, or declaration stating the information provided should be use as a source influencing any decisions on medical, diagnosis or treatment, or advice about what providers to use. The Site is an informational resource used for educational purposes only and cannot be used as a source used to make changes to medical treatment or lifestyle decisions without first consulting with your physician.